Oseltamivir induces favorable response on oxidative damage in the brain of rats treated with Bezafibrate

• Published in: International journal of neuroscience Vol. 132; no. 6; pp. 574 - 581
• Main Authors: Calderón Guzmán, David, Osnaya Brizuela, Norma, Ortiz Herrera, Maribel, Juárez Olguín, Hugo, Veloz Corona, Quetzalli, Sanchez Reyes, Lulu, Valenzuela Peraza, Armando, Barragán Mejía, Gerardo
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.06.2022
• Subjects: 5-HIAA; Adenosine Triphosphatases - metabolism; Animals; Bezafibrate; Bezafibrate - pharmacology; Brain - metabolism; Dopamine; Glutathione - metabolism; Hydrogen Peroxide - pharmacology; Hydroxyindoleacetic Acid - pharmacology; Lipid Peroxidation; Male; oseltamivir; Oseltamivir - pharmacology; oxidative damage; Oxidative Stress; Rats; Rats, Wistar; oxidative damage; oseltamivir; Bezafibrate; 5-HIAA; dopamine
• ISSN: 0020-7454; 1563-5279; 1543-5245
• DOI: 10.1080/00207454.2020.1828882

The purpose was to measure the effect of Oseltamivir on oxidative biomarkers and dopaminergic and serotonergic systems in brain of rats with induced hypotriglyceridemia by Bezafibrate. Male young Wistar rats were treated as follows: group 1, NaCl 0.9%, (Controls); group 2, Oseltamivir (100 mg/kg); group 3, single dose of Bezafibrate (150 mg/kg); group 4, four dose of Bezafibrate; group 5, single dose of Bezafibrate + Oseltamivir and group 6, four doses of Bezafibrate + Oseltamivir. Drugs were given orally. Triglycerides, Dopamine, 5-hydroxyindoleacetic acid (5-HIAA), Glutathione (GSH), Hydrogen peroxide (H 2 O 2) , lipid peroxidation, as well as total ATPase activity were measured using validated methods. Oseltamivir treated animals showed lower GSH and lipid peroxidation levels and an increment in 5-HIAA in the three evaluated brain regions. Treatment with Oseltamivir also reduces H 2 O 2 in the cortex and cerebellum/medulla oblongata. ATPase enzyme increased in these regions in the groups that were administered with Bezafibrate in repeated doses and in combination with Oseltamivir in single dose. Dopamine concentrations decreased in groups treated with Oseltamivir in the three evaluated regions. Also, there was a decrease in dopamine concentrations in the cerebellum/medulla oblongata of the animals treated with the combination of Oseltamivir and Bezafibrate. Innovation and conclusion: Animals with bezafibrate induced hypo-triglyceridemia that received Oseltamivir, either in single or repeated doses, have a higher improvement of their antioxidant activity and also experienced changes in the dopaminergic and serotonergic system in their brain, intending establish the beneficial of joint administration of both drugs in obese patients.